After Brensocatib Success, Insmed Targets ARIKAYCE FDA Indication Expansion

Insmed Incorporated, a U.S. biopharmaceutical company, plans to seek additional approvals for its MAC lung disease treatment ARIKAYCE from the U.S. Food and Drug Administration and Japanese regulators later this year. The company said that in the Phase 3b ENCORE study announced in March, ARIKAYCE delivered statistically significant improvements in patient-reported respiratory symptoms and sputum culture conversion rates versus standard multidrug therapy. Insmed intends to submit those data by the second half of 2026, aiming to broaden its current Limited Population pathway indication—now restricted to refractory MAC patients—to include individuals at earlier disease stages. If approved, the target patient population for ARIKAYCE could increase from roughly 30,000 to over 200,000, the company noted.

Headquartered in Bridgewater, New Jersey, Insmed specializes in treatments for rare and serious respiratory diseases. The company first drew attention in 2018 when ARIKAYCE received accelerated approval and a Limited Population label from the FDA as the first and only therapy specifically indicated for refractory Mycobacterium avium complex lung disease. Since then, Insmed has pursued an indication-expansion strategy. In August 2025, it secured FDA approval for BRINSUPRI (brensocatib), the first and only therapy approved for non-cystic fibrosis bronchiectasis (NCFB), giving the company its second commercial product. Leveraging its unique status, BRINSUPRI demonstrated revenue growth in its first year on the market.

Insmed’s first-quarter results and corporate developments further underscore its regulatory and pipeline momentum. Q1 revenue rose to $306.0 million from $92.8 million a year earlier, driven by $207.9 million in BRINSUPRI sales and $98.1 million from ARIKAYCE. The company reiterated its goal of at least $1 billion in full-year 2026 revenue and positive cash flow in 2027. Meanwhile, Insmed is advancing inhaled treprostinil TPIP through multiple Phase III trials targeting rare pulmonary vascular diseases—PALM-PAH, PALM-ILD, PALM-PPF and PALM-IPF—on a rolling basis.

Separately, a May 18 SEC filing disclosed that Chairman and CEO William Lewis, under a pre-arranged Rule 10b5-1 trading plan, exercised stock options and sold 25,564 common shares.